How much are GLP-1s if my insurance wont pay for them
RCT SUMMIT - Tirzepatide vs Placebo for Heart Failure with Preserved Ejection Fraction and Obesity, NEJM (2024) [PubMed abstract] The SUMMIT trial enrolled 731 patients with heart failure, an ejection fraction of at least 50%, and a BMI of 30 or more Main inclusion criteria Age 40 years NYHA class II-IV EF 50% BMI 30 KCCQ-CSS of 80 or lower Main exclusion criteria Cardiomyopathy Uncontrolled hypertension History of bariatric surgery HbA1c 9.5% Baseline characteristics Age - 65.3 years Female sex - 53.8% NYHA class: II - 72.5% | III or IV - 27.5% Average body weight - 227 lbs (103 kg) Average BMI - 38.3 Average EF - 60.8% History of CAD - 30% Median NT-proBNP level - 183 pg/ml Average GFR - 64.4 ml/min Average KCCQ-CSS score - 53.6 Heart failure exacerbation within 12 months - 46.9% Atrial fibrillation - 25.5% Type 2 diabetes - 48.2% Randomized treatment groups Group 1 (364 patients): Tirzepatide with a target dose of 15 mg once weekly Group 2 (367 patients): Placebo Tirzepatide was started at 2.5 mg once weekly and increased by 2.5 mg every 4 weeks as tolerated (1) Composite of adjudicated death from cardiovascular causes or a worsening heart-failure event
Thorne Glutathione-SR Product Description Youve probably heard of Glutathione if you follow the supplements industry, but if not here is what you need to know: It is the LeBron James of antioxidants
The discovery of the mTOR enzyme also uncovered a fascinating mechanism of metabolic controls in the cell, where mTOR acts as a major regulator of cell metabolism and is heavily involved in stem cell differentiation, acting as a sort of integrated metabolic switch and fuel sensor of oxygen, amino acids, and energy supply
Journal of Cutaneous Pathology, 36 (9), 9951000
Treatment initiation may be accompanied by closer clinical follow-up, lifestyle advice and increased patient engagement, which may influence suicide risk independent of GLP-1 RA effects
